Summary & Overview
HCPCS J0211: Sodium Nitrite and Sodium Thiosulfate Injection (Nithiodote)
HCPCS Level II code J0211 identifies the injectable combination of sodium nitrite 3 mg and sodium thiosulfate 125 mg, branded as Nithiodote. This code denotes a specific antidotal therapy used in acute care settings for toxic exposures where these agents are indicated. Nationally, accurate coding for antidotes like J0211 matters for timely treatment documentation, drug utilization tracking, and payer adjudication for high-cost, time-sensitive therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the product, typical sites of service, common billing modifiers, and which payers are included in comparative coverage discussions. The publication summarizes reimbursement benchmarks where available, highlights relevant policy considerations for coverage and prior authorization, and situates J0211 within acute care service lines.
The content is intended for billing managers, revenue cycle analysts, pharmacy directors, and policy teams seeking a national view of how this HCPCS Level II code is used and reimbursed across major payers. Data not available in the input is noted explicitly where applicable.
Billing Code Overview
HCPCS Level II code J0211 describes the combined injection product containing sodium nitrite 3 mg and sodium thiosulfate 125 mg (Nithiodote). This formulation is used as an antidote therapy for certain poisonings and cyanide exposures.
Service Type: Antidote/antitoxin injection
Typical Site of Service: Emergency department, inpatient hospital, or other acute care settings where parenteral antidote administration is provided
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult who presents to the emergency department, hospital inpatient unit, or designated outpatient infusion center with confirmed or suspected cyanide poisoning from inhalation, smoke inhalation from structural fires, nitroprusside toxicity, or industrial exposure. After clinical assessment (vital signs, neurologic exam, lactate, arterial blood gases, and exposure history) and laboratory confirmation when available, the treating physician authorizes administration of the antidote kit containing sodium nitrite and sodium thiosulfate (Nithiodote) to rapidly convert hemoglobin to methemoglobin and facilitate cyanide detoxification.
The clinical workflow includes immediate triage and airway/oxygen support, IV access establishment, baseline cardiac monitoring, informed consent if the patient is able, preparation of the labeled injectable doses, administration of J0211 per institutional protocol (sodium nitrite 3 mg and sodium thiosulfate 125 mg), observation for hemodynamic and methemoglobinemia effects, repeat dosing only when indicated, and documentation of dose, time, indication, patient response, and any adverse events in the medical record. Disposition decisions (observation, intensive care admission, or discharge) are based on clinical response and laboratory trends.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier information |